Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid abnormalities. In this Perspectives in Diabetes article, we emphasize that changing demographics and lifestyles over the past few decades have resulted in an epidemic of the “atherogenic dyslipidemia complex,” the main features of which include hypertriglyceridemia, low HDL cholesterol levels, qualitative changes in LDL particles, accumulation of remnant lipoproteins, and postprandial hyperlipidemia. We briefly review the underlying pathophysiology of this form of dyslipidemia, in particular its association with insulin resistance, obesity, and type 2 diabetes, and the marked atherogenicity of this condition. We explain the failure of existing classes of therapeutic agents such as fibrates, niacin, and cholesteryl ester transfer protein inhibitors that are known to modify components of the atherogenic dyslipidemia complex. Finally, we discuss targeted repurposing of existing therapies and review promising new therapeutic strategies to modify the atherogenic dyslipidemia complex. We postulate that targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich lipoprotein particles, represents a new frontier in CVD prevention and is likely to prove the most effective strategy in correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance with increased circulating FAs and decreased insulin signalling can also lead to increased chylomicron secretion.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
In the citing paper
“This milieu drives increased VLDL secretion, which is particularly enhanced when FA and insulin are in excess.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cited by
Items 201–211 of 211
A., D. P., Prabakaran, K., & Kuppusamy, D. B. (2025) · Current Applied Science and Technology · doi:10.55003/cast.2025.262219
Structure Modeling and Virtual Screening with HCAR3 to Discover Potential Therapeutic Molecules
Liu, Y., Peng, Y., Zhao, Z., Guo, Y., Lin, B., & Chiang, Y. (2025) · Pharmaceuticals · doi:10.3390/ph18091290
Development and validation of a nomogram model for predicting postprandial hypertriglyceridemia
Gu, W., Shi, L., Li, X., Zheng, K., & Song, G. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1622385
Filardi, P. P., Arcangeli, E., Carullo, P., Galeone, C., & Arca, M. (2025) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2025.3503 · Cited by 1
Nanomedicines for precise therapy in hyperlipidemia and obesity
Bhattamisra, S. K., Boddu, P., Kundu, A., Radha, G. V., Mondal, S., Rajkumar, J., Sahu, K., Singha, R., & Goswami, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28942-2.00010-7
Huh, J. H., Han, K.-D., Cho, Y. K., Roh, E., Kang, J. G., Lee, S. J., & Ihm, S.-H. (2022) · Figshare · doi:10.6084/m9.figshare.21485713
Bagheri, P., Khalili, D., Seif, M., & Rezaianzadeh, A. (2021) · Figshare · doi:10.6084/m9.figshare.14266930
Mahmeed, W. M. A., Al-Kindi, M., Al-sarraf, A., Amin, H., Zirie, M. A., Alawadi, F., Sabbour, H. M., Al-Waili, K., Lessan, N. G., Tikriti, A. A., et al. (2026) · Angiology · doi:10.1177/00033197261422789 · Cited by 2
Anthropometric and Metabolic Traits Across Ancestries in the UK Biobank
Roshandel, D., Paterson, A. D., & Dash, S. (2026) · Journal of Obesity · doi:10.1155/jobe/5149353
“IR-associated hyperinsulinemia and increased lipid fux due to reduced storage capacity also contribute to increased TG and TG-rich lipoprotein production from the liver and gut and reduced HDL [6, 7].”
Self-citationDebone, D., Vetromilla, B. M., de Azeredo-da-Silva, A. L. F., & de Oliveira, I. A. G. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i9.8616
Qadir, A. M., Omer, R. A., Barzani, H. A. H., & Sulaiman, S. H. (2026) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025603581
Metadata
- Authors
- Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F.
- Affiliations
- University of Toronto (CA)
- Western University (CA)
- Corresponding author
- Lewis, Gary F.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2016-06-13
- Volume
- 65
- Issue
- 7
- Pages
- 1767-1778
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2472281584
- Cited by
- 212
- References
- 137
- Citations by year
- 2026: 6 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 25 · 2018: 13 · 2017: 12 · 2016: 2
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP‑79533), MOP13430, MOP-43839)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- residual cardiovascular risk, hypertriglyceridemia, low HDL cholesterol, remnant lipoproteins, postprandial lipemia, triglyceride-rich lipoproteins, insulin resistance, type 2 diabetes, obesity, fibrates, nicotinic acid, cholesteryl ester transfer protein inhibitors, drug repurposing, cardiovascular disease prevention
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.